Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65](S0302283816002724)(10.1016/j.eururo.2016.03.015)

Boris Gershman, Holly K. Van Houten, Jeph Herrin, Daniel M. Moreira, Simon P. Kim, Nilay D Shah, Robert Jeffrey Karnes

Research output: Contribution to journalComment/debate

Abstract

We wish to report two typographical errors that recently came to our attention in this article. (1) The correct affiliation for Dr. R. Jeffrey Karnes is “a Department of Urology, Mayo Clinic, Rochester, MN, USA” rather than “d Health Research and Educational Trust, Chicago, IL, USA”.(2) In the first paragraph of the Discussion, the text “a concurrent 22% decrease” should be “a concurrent 10% decrease.” Similarly, in paragraph 5, the text “an absolute 22% reduction” should be “an absolute 10% reduction.” The remainder of the article correctly specifies the “10%” reduction in 30-d complication rates, and the findings and conclusions remain unaltered.Conflicts of interest: The authors have nothing to disclose.

Original languageEnglish (US)
Pages (from-to)e160
JournalEuropean Urology
Volume71
Issue number5
DOIs
StatePublished - May 1 2017

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Corrigendum re: “Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications” [Eur Urol 2017;71:55–65](S0302283816002724)(10.1016/j.eururo.2016.03.015)'. Together they form a unique fingerprint.

  • Cite this